Tumor Necrosis Factor Receptor Associated Factor 2 Signaling Provokes Adverse Cardiac Remodeling in the Adult Mammalian Heart

Divakaran et al: TRAF2 Mediated Cardiomyopathy

Vijay G. Divakaran, M.D.2
Sarah Evans, Ph.D.1
Veli K. Topkara, M.D.1
Abhinav Diwan, M.D.1
Jana Burchfield, Ph.D.2
Feng Gao, M.D.2
Jianwen Dong, Ph.D.2
Huei-Ping Tzeng, Ph.D.1
Natarajan Sivasubramanian, Ph.D.2
Philip M. Barger, M.D.1
Douglas L. Mann, M.D.1

Center for Cardiovascular Research, Division of Cardiology,1 Department of Medicine, Washington University School of Medicine, St. Louis, Missouri 63110 and
Winters Center for Heart Failure Research Section of Cardiology,2 Baylor College of Medicine, Houston, TX 77030

Correspondence to:
Douglas L. Mann, MD
Division of Cardiology
660 S. Euclid Ave, Campus Box 8086
St. Louis, MO 63110
Phone: (314) 362-8908
Fax: (314) 454-5550
Email: dmann@dom.wustl.edu

DOI: 10.1161/CIRCHEARTFAILURE.112.000080

Journal Subject Codes: Heart failure:[11] Other heart failure, Basic science research:[131] Apoptosis, Basic science research:[130] Animal models of human disease
Abstract

**Background**—Tumor necrosis factor (TNF) superfamily ligands that provoke a dilated cardiac phenotype signal through a common scaffolding protein termed TNF receptor associated factor 2 (TRAF2); however, virtually nothing is known with regard to TRAF2 signaling in the adult mammalian heart.

**Methods and Results**—We generated multiple founder lines of mice with cardiac restricted overexpression of TRAF2 and characterized the phenotype of mice with higher expression levels of TRAF2 (MHC-TRAF2HC). MHC-TRAF2HC transgenic mice developed a time-dependent increase in cardiac hypertrophy, LV dilation and adverse LV remodeling, and a significant decrease in LV \(+dP/dt\) and \(-dP/dt\) when compared to littermate (LM) controls (\(p < 0.05\) compared to LM). During the early phases of LV remodeling there was a significant increase in total matrix metalloproteinase (MMP) activity that corresponded with a decrease in total myocardial fibrillar collagen content. As the MHC-TRAF2HC mice aged, there was a significant decrease in total MMP activity accompanied by an increase in total fibrillar collagen content and an increase in myocardial tissue inhibitor of metalloproteinase-1 levels. There was a significant increase in NF-\(\kappa\)B activation at 4 – 12 weeks and JNK activation at 4 weeks in the MHCs TRAF2HC mice. Transciptional profiling revealed that > 95% of the hypertrophic/dilated cardiomyopathy-related genes that were significantly upregulated genes in the MHC-TRAF2HC hearts contained \(\kappa\)B elements in their promoters.

**Conclusions**—These results show for the first time that targeted overexpression of TRAF2 is sufficient to mediate adverse cardiac remodeling in the heart.

**Key Words**: tumor necrosis factor superfamily, dilated cardiomyopathy, inflammation, TNF receptor associated factor 2
Sustained inflammatory signaling in the heart leads to the development of a cardiomyopathy that is characterized by left ventricular (LV) dilation, LV dysfunction and myocardial fibrosis. If the inciting cause for the inflammation is resolved (e.g. viral myocarditis or sepsis), the cardiomyopathy is often fully reversible, even though the extent of LV dysfunction may have been quite severe. If, on the other hand, inflammation is sustained, and/or the inciting agent is persistent (e.g. Chagas disease), sustained inflammatory signaling frequently leads to the development of an irreversible cardiomyopathy. Although a number of pro-inflammatory cytokines have been implicated in this process, the cytokine that has been characterized most extensively thus far is tumor necrosis factor (TNF [TNFSF2]). Indeed, mice with cardiac-restricted overexpression of TNF in the heart demonstrate consistent morphological and structural changes in the myocardium including left ventricular (LV) wall thinning, LV dilatation, LV dysfunction, and increased myocardial fibrillar collagen content that overlaps the phenotype observed in inflammation-induced dilated cardiomyopathy. 1-3

TNF is the prototypical member of the TNF superfamily (TNFSF), which consists of 19 well-characterized ligands and 34 TNF superfamily receptors (TNFRSF). Members of the TNF superfamily of ligands and receptors are expressed in a broad variety of cell types, including myocardial cells.4 Without exception, all members of the TNF superfamily exhibit pro-inflammatory activity. Of note, recent studies have identified a potential role for TNF superfamily ligands/receptors in terms of mediating inflammatory responses in the heart, including FasL/Fas (TNFSF6/TNFRSF6), TWEAK (tumor necrosis factor-like weak inducer of apoptosis) /TWEAKR (TNFSF12/TNFRSF12),5 and RANKL (Receptor activator of NF-kB ligand)/ RANK (TNFSF11/TNFRSF11A).6 Although cardiac-restricted overexpression of FasL
does not lead to a dilated cardiomyopathy, overexpression of TNF, TWEAK and RANKL are each sufficient to provoke a dilated cardiac phenotype. In contrast to FasL, TNF, TWEAK and RANKL signal through TNFSF receptors that engage a common scaffolding protein termed TNF receptor associated factor 2 (TRAF2), that is recruited to the TNFSF receptors following engagement of their cognate ligands. Importantly, TRAF2 engages downstream signal transduction pathways that have been implicated in the development of a dilated cardiac phenotype, including mitogen activated protein kinases, NF-κB and c-jun N-terminal kinases (JNK). Taken together, these observations suggested the interesting possibility that TRAF2 may coordinate the signaling events that contribute to the changes in LV structure and function that occur during inflammation-induced cardiomyopathy. To address this question, we generated lines of transgenic mice with cardiac-restricted overexpression of TRAF2. Here we show for the first time that cardiac-restricted overexpression of TRAF2 is sufficient to mediate adverse cardiac remodeling in the heart, and thus phenocopies many aspects of the deleterious effects of TNF superfamily ligand signaling.

Methods

Transgenic Mice

We generated founder lines of transgenic mice with cardiac-restricted expression of murine tumor necrosis factor receptor associated factor 2 (TRAF2), using the alpha-myosin heavy chain (MHC) promoter (a gift from Jeff Robbins) to target TRAF2 to the cardiac myocyte, as described. Mice expressing the highest copy number of TRAF2 (referred to here as MHC-TRAF2_HC) were selected for further study. The MHC-TRAF2_HC lines of mice were generated
and maintained on an FVB background. Age matched littermate mice (LM) that lack the transgene were used as controls in these experiments.

All experiments were approved by the Institutional Animal Care and Use Committees at the Baylor College of Medicine and Washington University School of Medicine and were conducted in accordance with the guidelines of the Baylor College of Medicine and Washington University School of Medicine, Animal Care and Research Advisory Committee and the rules governing animal use, as published by the NIH.

**Characterization of MHC-TRAF2_{hc} Mice**

MHC-TRAF2_{hc} and LM control mice were evaluated at 4, 8 and 12 weeks age using standard morphometric and histological analyses. Cardiac hypertrophy was evaluated by determining the heart-weight to body-weight ratio, as described. Histologic assessment of cardiac myocyte dimensions was performed using lectin staining. Briefly, myocardial samples were deparaffinized, hydrated, and incubated with *Triticum vulgaris* Lectin-TRITC conjugate. Nuclei were stained with DAPI (Vector Labs, Burlingame, CA, USA). Myocardial sections (endocardial, mid-myocardial, and epicardial) were examined under 400x magnification (Nikon Eclipse E800, Nikon Inc.), and the outline of cardiac myocytes was traced using Metavue software (v6.1, Universal Imaging Corp.). We measured the length and diameter (at the level of the nucleus) of cardiac myocytes that had clearly identified intercalated disks. A minimum of 100 myocytes was examined at the endocardial, mid-myocardial, and epicardial levels for each treatment group, and the results averaged. Myocardial ultrastructure was examined in the hearts of 12 week LM and MHC-TRAF2_{hc} mouse hearts by transmission electron microscopy, as described.
**LV Structure and Function.** LV structure and function were assessed using 2D directed M-mode echocardiography as described previously (see Supplemental Material for details).12

**Extracellular Matrix.** Deparaffinized sections of perfusion fixed hearts from 4, 8 and 12 week old MHC-TRAF2HC and littermate control mice were stained using the picrosirius red technique, as described (see Supplemental Material for details).1 MMP activity from 4, 8 and 12 week old MHC-TRAF2HC and LM control mouse hearts were obtained using gelatin zymography, as previously described (see Supplemental Material for details).13 The intensity of the zymographic bands was quantified by image analysis software (Image-J, NIH). Levels of TIMP-1 were measured in myocardial extracts from MHC-TRAF2HC mice and littermate controls at 4, 8 and 12 weeks of by ELISA (Amersham RPN 2611), according to manufacturer’s recommendations.1

**Cell Death.** Cardiac myocyte apoptosis was assessed in the hearts of 4, 8 and 12 week LM and MHC-TRAF2HC mice by TUNEL, using a commercially available kit (In-Situ Cell-Death Detection Kit; Roche Applied Science, Mannheim, Germany), according to the manufacturer’s suggestions. Cardiac myocytes were distinguished from non-myocyte cell types within the myocardium, as described.14 Sections were counterstained with the nucleic acid binding dye, 4’,6’-diamidino-2-phenylindole hydrochloride ([DAPI]; Vector Labs) to visualize the total number of myocyte nuclei in each myocardial section. The number of TUNEL positive nuclei per high-power field (400 x) was determined in 8 randomly selected fields by an investigator blinded to the experimental group being studied. We also examined for the presence or absence of myocyte cell necrosis at 4 weeks by Evans Blue dye (EBD) staining. Briefly, mice were injected intraperitoneally with 1% EBD (1% w/v [Sigma #E-2129, St. Louis, MO]) in PBS (filter sterilized) and sacrificed after 18 hours.15 Hearts were excised, cannulated and rinsed with
10ml PBS (1ml/min) followed by 10ml Z-fix fixative. Hearts were then paraffin-embedded and sectioned. Fluorescence microscopy (200x) was then performed using a filter set with an excitation of 510 - 560 nm and an emission of 590 nm.

**NF-κB activation and JNK activity.** Activation of NF-κB in nuclear extracts obtained from 4 -12 MHC-TRAF2_HC and LM control mice was determined by electrophoretic mobility-shift assays (EMSAs), using an NF-κB oligonucleotide consensus sequence (5'-AGT TGA GGG GAC TTT CCC AGG C-3' [Santa Cruz Biotechnology, Santa Cruz, CA]), as described. The specificity of binding was determined by competition with a 20X molar excess of the respective unlabeled oligonucleotide. NF-κB activation was also assessed at 12 weeks in nuclear extracts obtained from 12 week MHC-TRAF2_HC, MHC-TRAF2_LC, and LM control hearts using a NF-κB factor family (p65 [RelA], p50, p52, RelB) ELISA (Active Motif, Carlsbad, CA), which was performed exactly according to manufacturer’s instructions. Data represent the average of duplicate samples from each heart. JNK activity was determined in littermate control and TRAF2 hearts at 4, 8 and 12 weeks of age, using the SAPK/JNK Assay kit (Cat # 9810 from Cell Signaling Technology, Inc., Danvers, MA), according to the manufacturer's instructions.

**Gene Expression Profiling in MHC-TRAF2_HC Hearts**

To identify potential molecular pathways responsible for the phenotype of the MHC-TRAF2_HC mice, gene expression profiling was performed. Briefly, Total RNA was extracted from the 4 LM controls hearts and 4 MHC-TRAF2_HC hearts using TRIzol reagent (Invitrogen, Carlsbad, CA) per the manufacturer’s instructions. RNA was further processes and hybridized to a Mouse Ref-8 Illumina BeadChip by the Genome Technology Access Center (GTAC) at Washington University School of Medicine and scanned with the BeadStation system from Illumina, Inc.
(San Diego, CA). Quality standards for hybridization, labeling, staining, background signal, and basal level of housekeeping gene expression for each chip were verified. After scanning the probe array, the resulting image was analyzed using the GenomeStudio software (Illumina, Inc., San Diego, CA). The background was subtracted, and log transformation and quantile normalization were performed. Differentially expressed genes between MHC-TRAF2_{HC} and LM control mice were determined using ANOVA testing with contrasts using Partek GS (Partek, St. Louis, MO), using an unadjusted p value < 0.05 and a fold change of 1.2 or greater. Changes in gene expression were analyzed by the SAM (Statistical Analysis of Microarray) program and plotted.\textsuperscript{16} Expected differentially expressed genes are reported on the x axis, whereas observed genes that were differentially expressed are displayed in the y axis. A false discovery rate (FDR) less than 5% was used for the SAM plots. Functional analysis and pathway analysis was performed using Database for Annotation Visualization and Integrated Discovery (DAVID).\textsuperscript{17}

Lists of genes that were significantly different in the MHC-TRAF2_{HC} mouse hearts were analyzed by KEGG (Kyoto Encyclopedia of Genes and Genomes) functional pathway analysis. Identification of potential κB sites within significantly dysregulated genes was performed using UCSC_TFBS option in the DAVID functional annotation tool.

**Statistical Analysis**

Data are expressed as a mean ± SEM. Two-way repeated analysis of variance (ANOVA) was used to test for differences between MHC-TRAF2_{HC} mice and littermate controls at 4, 8 and 12 weeks of age. Post-hoc ANOVA testing was performed between groups at individual time points, where appropriate, using the Tukey test. Differences in LV ventricular dimension, +dP/dt and -+dP/dt, and necropsy data between the MHC-TRAF2_{HC} mice and their LM controls were
performed using a non-paired Student’s t-test. All data analyses were performed using commercially available statistical software (STATVIEW version 5.0, SAS institute Inc., Cary, North Carolina). Significant differences were said to exist at p < 0.05.

Results
Characterization of MHC-TRAF2_{HC} Mice
The generation and characterization of the transgenic founder lines with targeted overexpression of murine TRAF2 is reported in the Supplemental Material. Founder lines that expressed $\geq 10$ copies of the transgene developed a dilated phenotype by 12 weeks of age that was similar to the phenotype observed in lines of mice with targeted overexpression of TNF$^{1,2}$. For the studies reported herein we selected mice that expressed 24 copies of the TRAF2 transgene, referred to herein as MHC-TRAF2_{HC} mice.

Morphology and ultrastructure. Figure 1 depicts the characterization of the MHC-TRAF2_{HC} mouse hearts in comparison to LM controls at 12 weeks of age. As shown, the MHC-TRAF2_{HC} mice develop a dilated cardiac phenotype (Figure 1A) characterized by an increased heart-weight-to-body ratio (Figure 1C). The increased heart-weight-to-body ratio was secondary to a significant increase in heart weight (mg) in the MHC-TRAF2_{HC} mice at 12 weeks (130.5±5.5 vs. 112.9±5.4, p < 0.05), insofar as the body weight (gm) was not different in the MHC-TRAF2_{HC} and LM control mice, respectively (25.5±0.8 vs. 24.1±0.8; p > 0.05), at 12 weeks. Light microscopic evaluation of the 12 week hearts from MHC-TRAF2_{HC} mice revealed that the histological appearance was similar to LM controls. Notably, there was no discernible inflammatory infiltrate (Figure 1B) by hematoxylin and eosin staining. Transmission electron microscopic evaluation of the 12 week LM hearts (Figure 1D and 1E) revealed a characteristic
linear array of sarcomeres and myofibrils. In contrast, the myofibrils in the 12 week old MHC-TRAF_{HC} mice were less organized, with loss of sarcomere registration, effacement of the Z-line, loss of the M-line, and accumulation of protein aggregates, consistent with the ultrastructural changes previously reported in MHCsTNF mice.\textsuperscript{1,18}

**LV Structure and Function.** As shown in Figure 2A, there was progressive increase in LV end-diastolic dimension (LVEDD) in the MHC-TRAF_{2HC} mice that was significantly (p < 0.05) different from LM controls by 8 weeks and 12 weeks. There was also a corresponding significant (p<0.05) increase in the r/h ratio in the MHC-TRAF_{2HC} mouse hearts at 12 weeks of age when compared to LM, consistent with adverse cardiac remodeling (Figure 2B). Importantly, the increase in r/h ratio was not secondary to decreased wall thickness in the MHC-TRAF_{2HC} mice, insofar as the LV wall thickness was similar in the LM and MHC-TRAF_{2HC} mice at 12 weeks of age (1.19 ± 0.08 vs. 1.16 ± 0.07, respectively, p > 0.05). The increase in heart-weight-to-body ratio in the MHC-TRAF_{2HC} mice at 12 weeks was accompanied by a ~ 24% increase in myocyte length (276.2 ± 3.5 \mu m vs. 222.5 ± 3.4 \mu m, p<0.001) and a corresponding ~ 11% decrease in myocyte width (50.9 ± 1.1 vs. 56.9 ± 1.8, p<0.01) compared to age matched LMs, consistent with cardiac myocyte elongation observed in eccentric remodeling of the heart. In order to determine whether targeted expression of TRAF2 resulted in LV dysfunction, as we have observed in lines of mice with targeted overexpression of TNF,\textsuperscript{19} we measured LV +dP/dt and –dP/dt ex vivo in a buffer perfused Langendorff apparatus. As shown in Figures 2C and 2D, there was a significant (p <0.01) decrease in peak +dP/dt and peak –dP/dt in 12 week MHC-TRAF_{2HC} mice when compared to LM controls.

**Extracellular Matrix.** To characterize the alterations in the extracellular matrix associated with LV remodeling in the MHC-TRAF_{2HC} mice, we evaluated time-dependent
changes in myocardial fibrillar collagen content using picrosirius red staining. Figure 3A shows representative histological sections of myocardium at 12 weeks, and Figure 3B summarizes the result of group data. As shown, LV myocardial fibrillar collagen content was similar (p>0.05) in MHC-TRAF2_{HC} and LM control hearts at 4 weeks. However, as the mice aged there was a significant (2.1 fold) increase in collagen content in the MHC-TRAF2_{HC} mice at 8 weeks (p=0.002) and a significant (4.4 fold) increase at 12 weeks (p=0.019) compared to LM controls, consistent with our prior observations in mice with targeted overexpression of TNF.

To determine whether the increased fibrillar collagen content in the MHC-TRAF2_{HC} mice was secondary to changes in matrix metalloproteinases (MMP) activity and/or myocardial levels of tissue inhibitors of metalloproteinase (TIMP) activity, we examined MMP activity and TIMP levels. Figures 3C and 3D show two important findings. First, there was a ~40% increase in MMP zymographic activity in the MHC-TRAF2_{HC} mice at 4 weeks of age compared to LM controls (p<0.05). However, at 8 and 12 weeks of age, the MMP activity in the MHC-TRAF2_{HC} mice declined significantly and was not significantly different (p > 0.05) in MHC-TRAF2_{HC} and LM hearts at 8 and 12 weeks. The decrease in MMP activity was accompanied by an increase in TIMP-1 levels, which were significantly greater (p < 0.05) in the MHC-TRAF2_{HC} mice by 12 weeks of age. Taken together, the decrease in MMP activity and increase in TIMP levels seen at 12 weeks of age is consistent with the increase in fibrosis observed in the MHC-TRAF2_{HC} mice at 12 weeks of age.

**Cell Death.** Previously, we have reported that cardiac remodeling in lines of transgenic mice with targeted overexpression of TNF develops progressive cardiac myocyte apoptosis that is secondary to activation of the intrinsic and extrinsic death pathways. Figure 4A illustrates representative fluorescent micrographs of TUNEL staining in MHC-TRAF2_{HC} at 12 weeks, and
Figure 4B summarizes the results of group data at 4, 8 and 12 weeks of age. As shown, the number of TUNEL positive nuclei was significantly increased (p < 0.05) in the MHC-TRAF2_{HC} hearts when compared to LM controls, whereas the prevalence of TUNEL positive nuclei was similar (p > 0.05) in MHC-TRAF2_{HC} and LM hearts at 8 and 12 weeks of age, suggesting that progressive cardiac myocyte apoptosis was unlikely to contribute to the progressive cardiac dilation observed in the MHC-TRAF2_{HC} mice at 8 and 12 weeks of age (Figure 1D). There was no evidence of myocyte necrosis in the MHC-TRAF2_{LC} or LM control hearts (see Supplemental Figure 3), consistent with our observations in the MHCsTNF mice.14

**NF-κB activation and JNK activity.** Previous studies suggest that the effects of TRAF2 in non-myocytes are mediated by activation of NF-κB and/or JNK.21 To determine whether these pathways were activated in the MHC-TRAF2_{HC} transgenic mouse hearts, we assessed NF-κB activation by EMSA and ELISA, as well as JNK activity. Figure 5A shows a representative EMSA at 12 weeks of age, whereas Figure 5B summarizes the results of group data at 4 - 12 weeks. The salient finding shown by Figure 5B is that NF-κB activation was significantly increased at 4, 8 and 12 weeks in the MHC-TRAF2_{HC} mice compared to LM control mice. The specificity of the DNA-protein interaction was determined by cold-chase experiments, which showed that the labeled NF-κB-DNA complexes were disrupted by a 20- fold excess of unlabeled oligonucleotide. As shown in Supplemental Figure 3, there was a significant increase in p50, RelB and p52 subunits in the MHC-TRAF2_{HC} hearts when compared to LM controls. Moreover, there was a significant increase in p50, RelB and p52 subunits in the MHC-TRAF2_{HC} hearts when compared to MHC-TRAF2_{LC} hearts, consistent with a gene dosage effect of TRAF2 on activation of canonical and non-canonical signaling in the MHC-TRAF2_{HC} mice. The important finding shown by Figure 5C is that although JNK activity was increased in the hearts
of the MHC-TRAF2\textsubscript{HC} mice at 4 weeks compared to LM, there was no significant difference in JNK activity at 8 and 12 weeks, consistent with our findings in the MHC-TRAF2\textsubscript{LC} mouse hearts.\textsuperscript{9}

**Transcriptional Profiling in MHC-TRAF2\textsubscript{HC} Mice**

To determine the mechanisms responsible for the dilated cardiac phenotype in the MHC-TRAF2\textsubscript{HC} mouse hearts we performed transcriptional profiling at 12 weeks of age. As shown by the SAM plot in Supplemental Figure 4A, 1136 genes were significantly upregulated and 823 genes were significantly downregulated in the 12 week MHC-TRAF2\textsubscript{HC} mouse hearts compared to LM controls. KEGG functional analysis (Supplemental Figure 4B) identified significant changes in gene expression in pathways implicated in both hypertrophic (\(p < 0.005\)) and dilated cardiomyopathy (\(p < 0.03\)) in the MHC-TRAF2\textsubscript{HC} compared to LM control hearts. Figure 6 displays a diagram of the cardiac hypertrophy/dilated cardiomyopathy related cardiac myocyte genes that were either upregulated or downregulated in the MHC-TRAF2\textsubscript{HC}, hearts compared to LM controls. Notably, genes that were involved with altered cytoskeletal linkage (\(\alpha 7\) integrin subunit, cytosolic actin, desmin, \(\alpha\)- and \(\gamma\)-sarcoglycan), decreased muscle contraction (\(\alpha\)- and \(\beta\)-myosin heavy chain, troponin I), impaired excitation contraction coupling (\(\beta\)-1,4 subunits of the dihydropyridine receptor, ryanodine receptor, and SERCA2A) and increased myocardial fibrosis (TGF-\(\beta 1\)) were altered in the transgenic mouse hearts (see Supplemental Table 2). Of the 37 cardiac hypertrophy/dilated cardiomyopathy pathway genes identified in the KEGG analysis, 35 genes (94.6\%) had predicted \(\kappa B\) sites when analyzed by the UCSC\_TFBS option in DAVID, consistent with the significant increase in NF-\(\kappa B\) activity observed in the MHC-TRAF2\textsubscript{HC} hearts.
Discussion

The results of this study, in which we generated and characterized lines of transgenic mice with cardiac restricted overexpression of TRAF2 (MHC-TRAF2_{HC}), demonstrate that TRAF2-mediated signaling leads to a dilated cardiac phenotype that overlaps the phenotype observed in transgenic mice overexpressing TNF superfamily ligands.\textsuperscript{1-3,5} The following lines of evidence support this statement. First, MHC-TRAF2_{HC} transgenic mice develop progressive left ventricular dilation (Figure 2A), cardiac hypertrophy (Figure 1C), and adverse cardiac remodeling (increased r/h ratio [Figure 2B]). Second, the 12 week MHC-TRAF2_{HC} mouse hearts had significantly decreased LV +dP/dt and −dP/dt when compared to LM controls (Figure 2C and 2D). Analysis of myocardial ultrastructure in 12 week old MHC-TRAF2_{HC} disclosed sarcomere disarray, with effacement of the Z-line and loss of the M-line, thus providing a potential ultrastructural explanation for the observed decline in LV systolic and diastolic function (Figure 1F and 1G). Third, LV dilation in the MHC-TRAF2_{HC} was accompanied by increased MMP activation at 4 weeks, followed by increased TIMP expression and increased myocardial fibrosis at 8 and 12 weeks, consistent with prior observations in the MHCsTNF transgenic mice (Figure 3A, 3B).\textsuperscript{22} Fourth, although we did observe increased myocyte apoptosis in the MHC-TRAF2_{HC} mice at 4 weeks (Figure 4B), the prevalence of cardiac myocyte apoptosis did not increase progressively over time, as observed in the MHCsTNF transgenic mice.\textsuperscript{10,14} The reasons for the differences in the prevalence of myocyte apoptosis in the two models are not clear, but may be related to the complexity of TRAF2-mediated signaling, which can transmit pro-death or pro-life signals depending on the context of TRAF2 activation.\textsuperscript{23} Finally, we observed increased NF-κB activation from 4-12 weeks (Figure 5B) and increased JNK activity at 4 weeks of age.
(Figure 5C) in the MHC-TRAF2<sub>HC</sub> mice, consistent with the known signaling pathways downstream from TRAF2.<sup>21</sup>

Although this study was not designed to delineate the specific signaling pathways that are responsible for heart failure phenotype in the MHC-TRAF2<sub>HC</sub> mice, our results suggest an important role for NF-κB signaling. As shown in Figure 6, the transcriptional profiling studies show that TRAF2 signaling leads to alterations in cardiac myocyte gene expression that have been associated with the development of heart failure, including alterations in the cytoskeleton genes, activation of “fetal” gene programs, changes in excitation contraction coupling, as well as alterations in genes that that regulate remodeling of the extracellular matrix. The observation that NF-κB activation persisted from 4-12 weeks and occurred pari passu with the development and progression of cardiac remodeling, coupled with the observation that ~95% of the genes identified in the KEGG cardiac hypertrophy/dilated cardiomyopathy functional pathway analysis (Figure 6 and Supplemental Table 2) contain predicted κB binding sites, suggests an important mechanistic role for TRAF2-mediated activation of NF-κB. Moreover, this point of view is consistent with a prior report which demonstrated that backcrossing TNF transgenic mice (TNF 1.6) with a transgenic mice expressing a cardiac-restricted dominant negative IκB transgene (“3M”) resulted in improved fractional shortening, decreased cardiac hypertrophy, and improved survival.<sup>24</sup> Data from the present study do not support a critical role for TRAF2-mediated JNK activation in the development of a dilated cardiac phenotype, insofar as JNK activation was not significant beyond 4 weeks of age in the MHC-TRAF2<sub>HC</sub> mice. The mechanism for the decrease in JNK signaling in the MHC-TRAF2<sub>HC</sub> from 8-12 weeks is not known, but is consistent with the known effects of NF-κB mediated dampening of JNK activation through GADD45β.<sup>25</sup>
**TRAF Mediated Signaling in the Heart**

TNF and its superfamily of ligands and receptors represent a double-edged sword for the cardiovascular system. That is, members of the TNF superfamily play an important role in mediating homeostatic response in the heart, as well as deleterious effects when activated either inappropriately and/or in a sustained manner.26 Relevant to this discussion, many of the TNF receptor superfamily members (e.g. type 1 TNF receptor [TNFR1, TNFRSF1A] and FAS) contain death domains that initiate signal transduction pathways that lead to caspase activation and apoptotic cell death, consistent with the known deleterious effects of TNFSF/TNFRSF signaling. Recently, a family of cytoplasmic proteins has been identified that is capable of both negatively and positively regulating apoptotic pathways, as well as inducing the expression of genes that promote cell survival. Members of this family of signal transduction molecules were first described because of their ability to bind to the type 2 TNF receptor (TNFR2, TNFRSF1B) and, therefore, were given the name TNF receptor-associated factors (TRAFs). Subsequent studies have demonstrated that TRAFs serve as adapter proteins for a wide variety of innate immune cell surface receptors, and play important roles in regulating not only apoptosis, but also in mediating stress responses. TRAF proteins are cytoplasmic adapter proteins that can interact directly with the intracellular domains of cell surface receptors (e.g.TNFR2), or can be recruited indirectly though adaptor proteins that bind directly to the cytoplasmic tail of the TNFRSF member (e.g. TRADD binding TNFR1). Recruitment of TRAF2 to the cytoplasmic domains of receptors leads to the assembly of signaling complexes that activate mitogen activated kinase kinase kinases that converge on JNK and NF-κB signaling.21 To date, seven mammalian TRAFs (TRAF1-7) have been identified, of
which TRAF 2, 3 and 6 are known to be expressed in the heart. With the exception of TRAF2, which is capable of upregulating cytoprotective pathways, and is cardioprotective when expressed at low levels, virtually nothing is known with regard to the role of TRAFs in the mammalian heart. Here we show that overexpression of TRAF2 in the heart phenocopies the dilated cardiomyopathic phenotype observed in TNF and sTWEAK transgenic mice. While the precise reasons for the beneficial and deleterious cardiac phenotypes in mice that express, respectively, low and high levels of TRAF2 is not known, our data suggest that these differences are related to a “gene dosage” effect, insofar as there was a significantly greater degree of activation of canonical and non-canonical NF-κB subunits in the MHC-TRAF2HC mouse hearts when compared to MHC-TRAF2LC mouse hearts (Supplemental Figure 3). Nonetheless, we cannot exclude the formal possibility that the effects observed in the MHC-TRAF2HC mice were non-specific, and were secondary to high levels of expression of the transgene, as has been reported for inert proteins that have been overexpressed in the heart.

Conclusions

This study shows for the first time that TRAF2-mediated signaling is sufficient to confer a heart failure phenotype in the adult mammalian heart. Given that TRAF2 associates directly or indirectly with the majority of TNF superfamily receptor members expressed in the heart (TNFR1, TNFR2, RANK and TWEAKR), and that the respective cognate ligands for these receptors, including TNF, RANKL, and TWEAK provoke a heart failure phenotype, the results of this study raise the interesting possibility that TRAF2 may serve as a nodal convergence point that orchestrates inflammatory responses in the heart following cardiac injury. Given that TRAF2 mediated signaling can be targeted through activation of GPR120 with omega-3 fatty
acids, which have been shown to be beneficial in heart failure, or possibly through disruption of E3 ligases which are essential for TRAF2 signaling, the current observations may have therapeutic importance as well.

**Acknowledgments**

The authors would like to acknowledge the technical assistance of Dorellyn Lee and Lora Staloch.

**Sources of Funding**

This research was supported by research funds from the N.I.H. (RO1 HL89543, R01 HL58081, RO1 HL11094, T32 HL 007706, T32 HL007081).

None.

**References**


Figure Legends

Figure 1. Characterization of MHC-TRAF2HC transgenic mice. (A) Photographs of whole hearts, coronal and sagittal sections of both LM and MHC-TRAF2HC mouse hearts (12 weeks). (B) Representative hematoxylin-eosin stained cross sections at the level of the papillary muscles (400x). (C) Heart-weight-to-body-weight ratio (mg/g) of LM and MHC-TRAF2HC at 8 and 12 weeks (n= 6-8 mice/group/time point) (*= p< 0.05 vs. LM at the indicated time point) (D-G) Representative transmission electron micrographs from 12 week MHC-TRAF2HC transgenic mice and LM at low (x7500, D,F) and high (x 60,000, E,G) magnification. Protein aggregates are enclosed by the circles.

Figure 2. LV structure and function. (A) 2-D echocardiographic assessment of left-ventricular end diastolic dimension (LVEDD) and (B) r/h (radius/wall thickness) ratio of 12 week LM and MHC-TRAF2HC at 4, 8 and 12 weeks (n= 6-8 mice/group/time point). (*= p< 0.05 vs. LM at the indicated time point) (C) LV +dP/dt and (D) LV –dP/dt assessed in 12 week in LM and MHC-TRAF2HC (n= 6 mice/group) (*= p< 0.05 vs. LM at 12 weeks).

Figure 3. Myocardial fibrillar collagen content, MMP activity and TIMP levels. (A) Representative picrosirius red staining (400x) for myocardial fibrillar collagen content in LM and MHC-TRAF2HC mice. (B) Group data for % collagen volume for LM control and MHC-TRAF2HC mice at 4, 8 and 12 weeks (n=5 mice/group/time point). (*= p< 0.05 vs. LM at the indicated time point) (C) Group data for total MMP zymographic activity (arbitrary densitometric units) in LM control and MHC-TRAF2HC at 4, 8 and 12 weeks of age weeks (n=5-6 mice/group/time point). (*= p< 0.05 vs. LM at the indicated time point) (D) TIMP-1 levels in LM control and MHC-TRAF2HC control mice at 4, 8
and 12 weeks of age. (n= 6-8 mice/group/time point). (*= p< 0.05 vs. LM at the indicated time point)

**Figure 4.** Prevalence of apoptosis. (A) Fluorescence microscopic (400x) images of TUNEL staining in LM control and MHC-TRAF2HC mice at 4 weeks of age. TUNEL stained apoptotic nuclei appear green. DAPI staining (blue) was used to determine the total nuclei per high power field. (B) Group data for prevalence of myocyte apoptosis in LM and MHC-TRAF2HC mice at 4, 8 and 12 weeks (n=5 mice/group/time point). (* p < 0.05 vs. LM at 4 weeks)

**Figure 5.** NF-κB activation and JNK activity. (A) Representative electromobility shift assay of NF-κB binding in nuclear extracts in 12 week littermate control (LM) and MHC-TRAF2HC (TG) mouse hearts. To determine the specificity of DNA-protein binding, nuclear extracts from MHC-TRAF2HC hearts were treated with a 20x excess of unlabeled oligonucleotide, and by supershift assays using polyclonal antibody directed against the p50 component of NF-κB (B) Densitometric quantification of NF-κB activity in 4, 8 and 12 week old LM and MHC-TRAF2HC mice. (n=3-5 mice per group per time point) (* p<0.05 vs. LM controls). (=*= p < 0.05 vs. LM at 4,8 and 12 weeks)  (C) Densitometric quantification of phospho-JNK activity using an in gel kinase assay in LM and MHC-TRAF2HC mice at 4, 8 and 12 weeks of age. (n=4 mice per group per time point) (* p < 0.05 vs. LM controls at 4 weeks).

**Figure 6.** Transcriptional profiling. KEGG functional analysis identified significant changes in gene expression in pathways implicated in both hypertrophic and dilated cardiomyopathy in the MHC-TRAF2HC compared to LM control hearts. The diagram illustrates the specific changes in
cardiac hypertrophy/dilated cardiomyopathy-related genes in relation to their anatomic location within the cardiac myocyte in MHC-TRAF2_{HC} hearts vs. LM controls at 12 weeks. Identification of potential κB sites within significantly dysregulated genes was performed using UCSC_TFBS option in the DAVID functional annotation tool. (Key: red triangles denote increased gene expression; green triangles denote decreased gene expression; * denotes genes containing predicted κB sites in the promoter)
A  Littermate  MHC-TRAF2\textsubscript{HC}

-\frac{dP}{dt} \text{ min} (\text{mmHg/sec})

<table>
<thead>
<tr>
<th></th>
<th>0</th>
<th>1000</th>
<th>2000</th>
<th>3000</th>
<th>4000</th>
</tr>
</thead>
<tbody>
<tr>
<td>D</td>
<td>*</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

LVEDD (mm)

<table>
<thead>
<tr>
<th></th>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
</tr>
</thead>
<tbody>
<tr>
<td>D</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

B  r/h ratio

<table>
<thead>
<tr>
<th></th>
<th>0</th>
<th>0.5</th>
<th>1.0</th>
<th>1.5</th>
<th>2.0</th>
</tr>
</thead>
<tbody>
<tr>
<td>D</td>
<td>*</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

C  dP/dt max (mmHg/sec)

<table>
<thead>
<tr>
<th></th>
<th>0</th>
<th>1000</th>
</tr>
</thead>
<tbody>
<tr>
<td>D</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

D  -\frac{dP}{dt} \text{ min} (\text{mmHg/sec})

<table>
<thead>
<tr>
<th></th>
<th>0</th>
<th>-1000</th>
<th>-2000</th>
<th>-3000</th>
</tr>
</thead>
<tbody>
<tr>
<td>D</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* indicates statistical significance.
Prevalence of apoptotic nuclei / field

Littermate

MHC-TRAF2HC

4 W 8 W 12 W

Littermate

MHC-TRAF2HC

Circulation

Heart Failure

Prevalence of apoptotic nuclei / field

4 W 8 W 12 W

*
Tumor Necrosis Factor Receptor Associated Factor 2 Signaling Provokes Adverse Cardiac Remodeling in the Adult Mammalian Heart

Vijay G. Divakaran, Sarah Evans, Veli K. Topkara, Abhinav Diwan, Jana Burchfield, Feng Gao, Jianwen Dong, Huei-Ping Tzeng, Natarajan Sivasubramanian, Philip M. Barger and Douglas L. Mann

_Circ Heart Fail._ published online March 14, 2013;

_Circulation: Heart Failure_ is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231

Copyright © 2013 American Heart Association, Inc. All rights reserved.

Print ISSN: 1941-3289. Online ISSN: 1941-3297

The online version of this article, along with updated information and services, is located on the World Wide Web at:

http://circheartfailure.ahajournals.org/content/early/2013/03/14/CIRCHEARTFAILURE.112.000080

Data Supplement (unedited) at:

http://circheartfailure.ahajournals.org/content/suppl/2013/03/14/CIRCHEARTFAILURE.112.000080.DC1

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in _Circulation: Heart Failure_ can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:

http://www.lww.com/reprints

Subscriptions: Information about subscribing to _Circulation: Heart Failure_ is online at:

http://circheartfailure.ahajournals.org//subscriptions/
DATA SUPPLEMENT TO:

Tumor Necrosis Factor Receptor Associated Factor 2 Signaling Provokes Adverse Cardiac Remodeling in the Adult Mammalian Heart

Methods/Results

Characterization of Founder Lines of MHC-TRAF2 Mice

The TRAF2 cDNA used for to generate the MHC-TRAF2 construct was the generous gift of Dr. Yongwon Choi. To facilitate separation of endogenous TRAF2 from the TRAF2 that was driven by the alpha-myosin heavy chain promoter, we FLAG-tagged the TRAF-2 construct using an EcoRV cleavage site with the primer sequence: CTA GGA TAT CCG TTT AGT GAA CCG TCA GAA TTG ATC TAC CAT GGA CTA CAA AGACGA TGA CGA CAA GGC TGC AGC CAG TGT GAC. The FLAG-tag was inserted at the N-terminus using a NotI cleavage site with the primer sequence: ACG TGC GGC CGC CTA GAG TCC TGT C. The transgene construct was injected into single cell embryos of FVB mice at the Baylor College of Medicine transgenic core facility. Founder lines of MHC-TRAF2 transgenic mice (FVB background) were identified by PCR and confirmed by Southern blotting using a 286 bp probe targeted to exon 8 of the TRAF2 gene (supplemental Figure IA). Western blotting was performed to confirm the expression of TRAF2 protein in the hearts of 12 week MHC-TRAF2HC mouse hearts (supplemental Figure IB) using an anti-TRAF2 antibody (sc-877, Santa Cruz Biotechnology, Santa Cruz, CA). Immunohistochemical staining of founder lines showed that TRAF2 protein was localized diffusely throughout the cytoplasm in MHC-TRAF2 mouse hearts compared to littermate control mice (supplemental Figure IC). We obtained three founder lines: 329W (7 copies of TRAF2 transgene); 330W (10 copies of transgene); 335W (24 copies of transgene).

Supplemental Table I displays the morphometrics of the MHC-TRAF2 founder lines of mice. The 329W line, with the lowest copy of the transgene, referred to as MHC-TRAF2LC, has been characterized in detail and reported previously. Mice with 10 and 24 copies of the TRAF2 transgene developed an increased heart-weight-to-body weight ratio and a dilated cardiac phenotype by 12 weeks of age. Lines of mice that
expressed 24 copies of the transgene (referred to here as MHC-TRAF2HC mice) were found to express ~ two-fold higher levels of TRAF2 protein compared to mice that expressed 7 or 10 copies by Western blot analysis (supplemental Figure 1B). Mice expressing 24 copies of the TRAF2 transgene (referred to here as MHC-TRAF2HC) were selected for further study.

REFERENCES


Supplemental Table I
Characterization of founder lines of mice with targeted overexpression of TRAF2

<table>
<thead>
<tr>
<th>Mice</th>
<th>Copy #</th>
<th>HW (mg)</th>
<th>BW (g)</th>
<th>HW/BW (mg/g)</th>
<th>Cardiac Phenotype</th>
</tr>
</thead>
<tbody>
<tr>
<td>MHC-TRAF2LC</td>
<td>7</td>
<td>132.0±7.3*</td>
<td>28.9±1.6</td>
<td>4.6±0.2*</td>
<td>Hypertrophy</td>
</tr>
<tr>
<td>LM</td>
<td>-</td>
<td>120.7±4.4</td>
<td>30.1±1.5</td>
<td>4.0±0.1</td>
<td></td>
</tr>
<tr>
<td>MHC-TRAF2IC</td>
<td>10</td>
<td>184.3±0.01*</td>
<td>25.7±1.2</td>
<td>7.2±0.5*</td>
<td>Dilated</td>
</tr>
<tr>
<td>LM</td>
<td>-</td>
<td>117.7±0.01</td>
<td>27.9±2.6</td>
<td>4.2±0.1</td>
<td></td>
</tr>
<tr>
<td>MHC-TRAF2HC</td>
<td>24</td>
<td>130.5±5.5*</td>
<td>25.5±0.8</td>
<td>5.3±0.1*</td>
<td>Dilated</td>
</tr>
<tr>
<td>LM</td>
<td>-</td>
<td>112.9±5.4</td>
<td>24.1±0.8</td>
<td>4.5±0.1</td>
<td></td>
</tr>
</tbody>
</table>

(Data are expressed as mean ± SEM. Necropsy data for heart weight (HW), body weight (BW), heart-weight-to-body-weight- ratio (HW/BW) and phenotype of 12 week old mice with varying copies of the TRAF2 transgene and 12 week littermate (LM) controls. (n ≥ 5 mice per group; * = p ≤ 0.05 vs. littermate control)
### Supplemental Table II: Changes in Gene Expression in MHC-TRAF2HC Mice

<table>
<thead>
<tr>
<th>Symbol</th>
<th>Gene Name</th>
<th>Expression level (relative to LM)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Increased</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MYH7</td>
<td>myosin, heavy chain 7, cardiac muscle, beta</td>
<td>14.92</td>
<td>7.61x10^{-05}</td>
</tr>
<tr>
<td>TGFβ3</td>
<td>transforming growth factor, beta 3</td>
<td>4.00</td>
<td>9.82x10^{-06}</td>
</tr>
<tr>
<td>TIMP1</td>
<td>Tissue inhibitor of metalloproteinase 1</td>
<td>3.39</td>
<td>2.82x10^{-3}</td>
</tr>
<tr>
<td>MMP23</td>
<td>Matrix metalloproteinase 23</td>
<td>2.88</td>
<td>5.252x10^{-3}</td>
</tr>
<tr>
<td>CACNB1</td>
<td>calcium channel, voltage-dependent, beta 1 subunit</td>
<td>2.60</td>
<td>8.49x10^{-04}</td>
</tr>
<tr>
<td>TGFβ2</td>
<td>transforming growth factor, beta 2</td>
<td>2.29</td>
<td>3.88x10^{-02}</td>
</tr>
<tr>
<td>DES</td>
<td>Desmin</td>
<td>2.22</td>
<td>9.84x10^{-05}</td>
</tr>
<tr>
<td>ITGA11</td>
<td>integrin, alpha 11</td>
<td>2.05</td>
<td>2.53x10^{-02}</td>
</tr>
<tr>
<td>PRKβ2</td>
<td>protein kinase, AMP-activated, beta 2 non-catalytic subunit</td>
<td>1.81</td>
<td>7.88x10^{-3}</td>
</tr>
<tr>
<td>COL1A1</td>
<td>collagen, type I, alpha 1</td>
<td>1.77</td>
<td>1.70x10^{-2}</td>
</tr>
<tr>
<td>COL3A1</td>
<td>collagen, type III, alpha 1</td>
<td>1.77</td>
<td>3.24x10^{-2}</td>
</tr>
<tr>
<td>MMP14</td>
<td>matrix metalloproteinase 14</td>
<td>1.65</td>
<td>2.96x10^{-2}</td>
</tr>
<tr>
<td>MMO2</td>
<td>matrix metalloproteinase 2</td>
<td>1.60</td>
<td>2.66x10^{-2}</td>
</tr>
<tr>
<td>ITGB5</td>
<td>integrin, alpha 5</td>
<td>1.51</td>
<td>4.16x10^{-02}</td>
</tr>
<tr>
<td>LMNA</td>
<td>lamin A/C</td>
<td>1.50</td>
<td>9.95x10^{-04}</td>
</tr>
<tr>
<td>ACTB</td>
<td>actin, beta</td>
<td>1.48</td>
<td>7.37x10^{-03}</td>
</tr>
<tr>
<td>TIMP2</td>
<td>Tissue inhibitor of metalloproteinase 2</td>
<td>1.38</td>
<td>1.44x10^{-2}</td>
</tr>
<tr>
<td>IGF1</td>
<td>insulin-like growth factor 1 (somatomedin C)</td>
<td>1.37</td>
<td>1.77x10^{-03}</td>
</tr>
<tr>
<td>MMP7</td>
<td>Matrix metalloproteinase 7</td>
<td>1.34</td>
<td>6.34x10^{-3}</td>
</tr>
<tr>
<td>MYBPC3</td>
<td>myosin binding protein C, cardiac</td>
<td>1.29</td>
<td>2.93x10^{-02}</td>
</tr>
<tr>
<td>ITGA5</td>
<td>integrin, alpha 5 (fibronectin receptor, alpha polypeptide)</td>
<td>1.28</td>
<td>3.42x10^{-02}</td>
</tr>
<tr>
<td></td>
<td>Decreased</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SGCA</td>
<td>sarcoglycan, alpha (50kDa dystrophin-associated glycoprotein)</td>
<td>-1.94</td>
<td>8.27x10^{-04}</td>
</tr>
<tr>
<td>TNNI3</td>
<td>troponin I type 3 (cardiac)</td>
<td>-1.66</td>
<td>2.39x10^{-03}</td>
</tr>
<tr>
<td>ITGA7</td>
<td>integrin, alpha 7</td>
<td>-1.65</td>
<td>6.78x10^{-03}</td>
</tr>
<tr>
<td>SGCG</td>
<td>sarcoglycan, gamma (35kDa dystrophin-associated glycoprotein)</td>
<td>-1.62</td>
<td>1.11x10^{-03}</td>
</tr>
<tr>
<td>ADCY6</td>
<td>adenylate cyclase 6</td>
<td>-1.59</td>
<td>2.05x10^{-03}</td>
</tr>
<tr>
<td>MMP15</td>
<td>matrix metalloproteinase 15</td>
<td>-1.57</td>
<td>1.43x10^{-3}</td>
</tr>
<tr>
<td>PRKAB1</td>
<td>protein kinase, AMP-activated, beta 1 non-catalytic subunit</td>
<td>-1.54</td>
<td>1.18x10^{-2}</td>
</tr>
<tr>
<td>ATP2A2</td>
<td>ATPase, Ca++ transporting, cardiac muscle, slow twitch 2</td>
<td>-1.47</td>
<td>1.37x10^{-02}</td>
</tr>
<tr>
<td>ITGB6</td>
<td>integrin, beta 6</td>
<td>-1.41</td>
<td>3.48x10^{-03}</td>
</tr>
<tr>
<td>TGFβ1</td>
<td>transforming growth factor, beta 1</td>
<td>-1.33</td>
<td>2.41x10^{-02}</td>
</tr>
<tr>
<td>ADCY4</td>
<td>adenylate cyclase 4</td>
<td>-1.31</td>
<td>3.09x10^{-03}</td>
</tr>
<tr>
<td>MYH6</td>
<td>myosin, heavy chain 6, cardiac muscle, alpha</td>
<td>-1.26</td>
<td>2.40x10^{-02}</td>
</tr>
<tr>
<td>RYR2</td>
<td>ryanodine receptor 2 (cardiac)</td>
<td>-1.25</td>
<td>2.84x10^{-02}</td>
</tr>
<tr>
<td>CACNG4</td>
<td>calcium channel, voltage-dependent, gamma subunit 4</td>
<td>-1.24</td>
<td>4.40x10^{-02}</td>
</tr>
</tbody>
</table>

Changes in gene expression in MHC-TRAF2HC mice vs. LM control mice at 12 weeks of age identified by the KEGG functional pathway for cardiac hypertrophy/dilated cardiomyopathy were modified to include changes in extracellular matrix gene expression that have been linked to the development of dilated cardiomyopathy. Changes in gene expressed are displayed visually in Figure 6 in the manuscript.
Supplemental Figure I: Generation of transgenic mice overexpressing TRAF2 in the heart. (A) Representative southern blot showing three lines of mice overexpressing 7, 10 and 24 copies of the TRAF2 transgene in comparison to controls. (B) Western blot of TRAF2 protein expression in hearts of MHC-TRAF2 mice expressing 7, 10 and 24 copies of the TRAF2 transgene. (C) Representative immunohistochemical staining of littermate and MHC-TRAF2HC mouse hearts (100 x).

Supplemental Figure II: Evans Blue dye uptake in littermate control and MHC-TRAF2HC mouse hearts. To determine the presence of absence of myocyte cell necrosis, 4 week littermate control and MHC-TRAF2HC mice were injected intraperitoneally with Evans Blue dye, the hearts excised, fixed and examined by fluorescence microscopy (200 x). As a positive control, littermate control mouse hearts were subjected to ischemia reperfusion injury ex vivo, and stained with Evan Blue dye as described.³
Supplemental Figure III: NF-κB subunits. An NF-κB ELISA was performed on nuclear extracts from obtained from 12 week littermate control and MHC-TRAF2$_{HC}$ mouse hearts (n = 6-9 hearts/group).

Supplemental Figure IV: Transcriptional profiling. (A) SAM plot of changes in gene expression in the 12 week MHC-TRAF2$_{HC}$ mouse hearts compared to LM controls (n = 4 hearts/group). Genes that were significantly increased are denoted by red circles; genes that were significantly decreased are denoted by green circles. A false discovery rate (FDR) less than 5% was used for the SAM plots. (B) KEGG analysis of functional pathways that were significantly different in the MHC-TRAF2$_{HC}$ compared to LM control hearts at 12 weeks of age.